Swiss National Bank Acquires New Stake in MBX Biosciences, Inc. $MBX

Swiss National Bank bought a new position in shares of MBX Biosciences, Inc. (NASDAQ:MBX) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 44,400 shares of the company’s stock, valued at approximately $1,325,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP grew its position in MBX Biosciences by 112.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,823,336 shares of the company’s stock valued at $84,408,000 after acquiring an additional 2,556,708 shares in the last quarter. Deep Track Capital LP lifted its position in shares of MBX Biosciences by 43.9% during the third quarter. Deep Track Capital LP now owns 3,150,000 shares of the company’s stock worth $55,125,000 after purchasing an additional 961,408 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of MBX Biosciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,817,811 shares of the company’s stock worth $57,334,000 after purchasing an additional 140,449 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of MBX Biosciences by 164.2% in the third quarter. Franklin Resources Inc. now owns 1,307,288 shares of the company’s stock valued at $22,878,000 after purchasing an additional 812,436 shares during the period. Finally, MPM Bioimpact LLC boosted its stake in shares of MBX Biosciences by 14.3% in the second quarter. MPM Bioimpact LLC now owns 1,294,416 shares of the company’s stock valued at $14,769,000 after purchasing an additional 161,466 shares during the period.

MBX Biosciences Stock Performance

MBX stock opened at $65.93 on Friday. The company’s 50 day moving average price is $48.63 and its 200 day moving average price is $39.05. MBX Biosciences, Inc. has a fifty-two week low of $9.63 and a fifty-two week high of $69.40. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of -29.83 and a beta of 0.16.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on MBX shares. Wall Street Zen raised shares of MBX Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday. Citizens Jmp boosted their price target on shares of MBX Biosciences from $76.00 to $86.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 12th. Mizuho upped their price objective on MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research report on Wednesday. Truist Financial increased their price objective on MBX Biosciences from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, Barclays lifted their target price on MBX Biosciences from $66.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $71.12.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.